|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1780 EUR | +0.56% |
|
+1.72% | +4.12% |
| 25-09-30 | Celyad Oncology to Sell Belgian Research Facility for EUR3 Million | MT |
| 25-09-29 | Celyad Oncology announces research facility divestiture | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -21.04 | -23.32 | -25.41 | -33.03 | -28 | |||||
Return on Total Capital | -38.76 | -42.08 | -49.82 | -99.63 | -83.59 | |||||
Return On Equity % | -44.91 | -71.05 | -170.72 | -159.08 | -170.92 | |||||
Return on Common Equity | -44.91 | -71.05 | -170.72 | -159.08 | -170.92 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | - | - | 32.35 | 93.55 | |||||
SG&A Margin | 188K | - | - | 6.13K | 1.72K | |||||
EBITDA Margin % | -512K | - | - | -8.83K | -3.06K | |||||
EBITA Margin % | -522K | - | - | -8.9K | -3.15K | |||||
EBIT Margin % | -525K | - | - | -9.33K | -3.16K | |||||
Income From Continuing Operations Margin % | -344K | - | - | -8.28K | -3.13K | |||||
Net Income Margin % | -344K | - | - | -8.28K | -3.13K | |||||
Net Avail. For Common Margin % | -344K | - | - | -8.28K | -3.13K | |||||
Normalized Net Income Margin | -331K | - | - | -5.86K | -1.96K | |||||
Levered Free Cash Flow Margin | -222K | - | - | -14.17K | -821.03 | |||||
Unlevered Free Cash Flow Margin | -218K | - | - | -14.12K | -781.05 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0 | - | - | 0.01 | 0.01 | |||||
Fixed Assets Turnover | 0 | - | - | 0.1 | 0.11 | |||||
Receivables Turnover (Average Receivables) | 0.01 | - | - | 0.16 | 0.74 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.67 | 2.48 | 1.42 | 3.79 | 2.29 | |||||
Quick Ratio | 1.53 | 2.34 | 1.31 | 3.34 | 1.79 | |||||
Operating Cash Flow to Current Liabilities | -2.34 | -1.93 | -2.69 | -5.18 | -2 | |||||
Days Sales Outstanding (Average Receivables) | 29.43K | - | - | 2.31K | 497.84 | |||||
Average Days Payable Outstanding | - | - | - | 15.86K | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 11.74 | 6.03 | 5.91 | 16.78 | 177.1 | |||||
Total Debt / Total Capital | 10.5 | 5.69 | 5.58 | 14.37 | 63.91 | |||||
LT Debt/Equity | 8.15 | 3.96 | 2.73 | 14.31 | 149.32 | |||||
Long-Term Debt / Total Capital | 7.29 | 3.74 | 2.58 | 12.25 | 53.88 | |||||
Total Liabilities / Total Assets | 53.1 | 45.41 | 78.1 | 61.28 | 94.85 | |||||
EBIT / Interest Expense | -88.35 | -106.81 | -102.85 | -116 | -49.33 | |||||
EBITDA / Interest Expense | -82.46 | -101.18 | -95.88 | -107.18 | -46.26 | |||||
(EBITDA - Capex) / Interest Expense | -82.96 | -102.47 | -96.5 | -118.15 | -46.26 | |||||
Total Debt / EBITDA | -0.15 | -0.1 | -0.01 | -0.12 | -0.16 | |||||
Net Debt / EBITDA | 0.56 | 1.06 | 0.65 | 0.68 | 0.6 | |||||
Total Debt / (EBITDA - Capex) | -0.15 | -0.1 | -0.01 | -0.11 | -0.16 | |||||
Net Debt / (EBITDA - Capex) | 0.55 | 1.05 | 0.64 | 0.61 | 0.6 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -16.67 | - | - | - | 82.35 | |||||
Gross Profit, 1 Yr. Growth % | -16.67 | - | - | - | 427.27 | |||||
EBITDA, 1 Yr. Growth % | -11.2 | 4.22 | -26.72 | -63.6 | -37.06 | |||||
EBITA, 1 Yr. Growth % | -11.15 | 3.74 | -27.26 | -63.56 | -35.73 | |||||
EBIT, 1 Yr. Growth % | -11.03 | 3.8 | -25.61 | -62.62 | -38.5 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -39.91 | 54.1 | 54.4 | -79.36 | -31.06 | |||||
Net Income, 1 Yr. Growth % | -39.91 | 54.1 | 54.4 | -79.36 | -31.06 | |||||
Normalized Net Income, 1 Yr. Growth % | -9.56 | 3.37 | -25.86 | -62.43 | -39.2 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -46.03 | 37.69 | 6.63 | -81.87 | -57.2 | |||||
Accounts Receivable, 1 Yr. Growth % | -3.42 | 6.84 | 115.4 | -58.2 | -66.84 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -18.61 | -21.15 | -90.49 | 492.23 | -18.42 | |||||
Total Assets, 1 Yr. Growth % | -26.44 | 20.97 | -75.34 | -17.42 | -39.02 | |||||
Tangible Book Value, 1 Yr. Growth % | -146.24 | -271.38 | -51.4 | 62.03 | -92.2 | |||||
Common Equity, 1 Yr. Growth % | -32.06 | 40.8 | -90.11 | 46.03 | -91.89 | |||||
Cash From Operations, 1 Yr. Growth % | -1.9 | -3.69 | 5.13 | -45.73 | -62.64 | |||||
Capital Expenditures, 1 Yr. Growth % | -64.03 | 120.67 | -62.84 | 630.89 | - | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -23.78 | 21.39 | -21.46 | 4.49 | -89.45 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -23.94 | 22 | -21.45 | 5.06 | -89.93 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -95.99 | - | - | - | - | |||||
Gross Profit, 2 Yr. CAGR % | -95.99 | - | - | - | - | |||||
EBITDA, 2 Yr. CAGR % | -9.52 | -1.87 | -10.5 | -41.91 | -52.05 | |||||
EBITA, 2 Yr. CAGR % | -10.09 | -3.86 | -12.99 | -42.14 | -51.52 | |||||
EBIT, 2 Yr. CAGR % | -9.98 | -3.9 | -12.13 | -40.9 | -51.97 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -32.2 | -3.77 | 54.25 | -43.55 | -62.28 | |||||
Net Income, 2 Yr. CAGR % | -32.2 | -3.77 | 54.25 | -43.55 | -62.28 | |||||
Normalized Net Income, 2 Yr. CAGR % | -8.56 | -3.31 | -12.46 | -40.86 | -52.12 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -39.39 | -13.79 | 21.17 | -56.03 | -72.14 | |||||
Accounts Receivable, 2 Yr. CAGR % | 19.41 | 1.58 | 51.7 | -5.11 | -62.77 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 16.9 | -19.89 | -72.61 | -24.94 | 119.81 | |||||
Total Assets, 2 Yr. CAGR % | -16.29 | -5.67 | -45.38 | -54.87 | -29.04 | |||||
Tangible Book Value, 2 Yr. CAGR % | -51.97 | -10.99 | -8.74 | -11.26 | -64.45 | |||||
Common Equity, 2 Yr. CAGR % | -25.33 | -2.19 | -62.68 | -61.99 | -65.6 | |||||
Cash From Operations, 2 Yr. CAGR % | 0.76 | -2.8 | 0.62 | -24.46 | -54.97 | |||||
Capital Expenditures, 2 Yr. CAGR % | -57.57 | -10.91 | -9.45 | 64.8 | - | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -14.6 | -3.81 | -2.36 | 3.53 | -66.77 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -15.21 | -3.67 | -2.11 | 3.97 | -67.44 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -88.78 | - | - | 173.24 | - | |||||
Gross Profit, 3 Yr. CAGR % | -88.18 | - | - | 87.58 | - | |||||
EBITDA, 3 Yr. CAGR % | 0.68 | -5.15 | -10.97 | -28.28 | -40.26 | |||||
EBITA, 3 Yr. CAGR % | 0.1 | -5.7 | -12.4 | -29.63 | -40.01 | |||||
EBIT, 3 Yr. CAGR % | -0.7 | -5.61 | -11.76 | -28.7 | -40.04 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -32.68 | -10.86 | 12.65 | -21.11 | -39.66 | |||||
Net Income, 3 Yr. CAGR % | -32.68 | -10.86 | 12.65 | -21.11 | -39.66 | |||||
Normalized Net Income, 3 Yr. CAGR % | -4.44 | -4.74 | -11.5 | -28.76 | -40.24 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -40.5 | -20.32 | -7.46 | -35.67 | -56.43 | |||||
Accounts Receivable, 3 Yr. CAGR % | 69.58 | 15.07 | 30.5 | -1.28 | -33.16 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 7.78 | 2.52 | -60.62 | -23.7 | -22.82 | |||||
Total Assets, 3 Yr. CAGR % | -5.22 | -5.36 | -39.68 | -37.31 | -50.11 | |||||
Tangible Book Value, 3 Yr. CAGR % | -26.69 | -26.61 | -27.25 | 10.51 | -60.54 | |||||
Common Equity, 3 Yr. CAGR % | -13.29 | -7.75 | -54.43 | -41.19 | -77.29 | |||||
Cash From Operations, 3 Yr. CAGR % | -14.61 | -0.75 | -0.23 | -18.09 | -40.26 | |||||
Capital Expenditures, 3 Yr. CAGR % | -43.93 | -26.48 | -33.43 | 81.64 | - | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -12.41 | -3.98 | -10.1 | 9.17 | -51.61 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -12.74 | -4.28 | -10 | 9.66 | -52.22 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.76 | - | - | -49.53 | 98.73 | |||||
Gross Profit, 5 Yr. CAGR % | 37.97 | - | - | -59.73 | 96.1 | |||||
EBITDA, 5 Yr. CAGR % | -2.01 | 2.06 | -4.86 | -22.04 | -27.15 | |||||
EBITA, 5 Yr. CAGR % | -1.79 | 1.75 | -5.42 | -22.43 | -27.55 | |||||
EBIT, 5 Yr. CAGR % | -2.22 | 1.24 | -5.44 | -21.73 | -27.59 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -9.99 | 2.35 | -6.21 | -25.75 | -27.28 | |||||
Net Income, 5 Yr. CAGR % | -9.99 | 2.35 | -6.21 | -25.75 | -27.28 | |||||
Normalized Net Income, 5 Yr. CAGR % | -1.68 | 2.98 | -7.73 | -21.28 | -27.56 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -18.5 | -7.69 | -20.92 | -37.19 | -42.75 | |||||
Accounts Receivable, 5 Yr. CAGR % | 44.82 | 50.86 | 62.19 | 6.53 | -20.98 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 29.38 | -1.83 | -37.69 | -9.5 | -21.66 | |||||
Total Assets, 5 Yr. CAGR % | -16.16 | -10.45 | -23.97 | -29.62 | -35.63 | |||||
Tangible Book Value, 5 Yr. CAGR % | -40.76 | -28.37 | -19.98 | -20.82 | -45.37 | |||||
Common Equity, 5 Yr. CAGR % | -22.59 | -13.65 | -38.11 | -35.3 | -59.28 | |||||
Cash From Operations, 5 Yr. CAGR % | 0.26 | 1.53 | -8.82 | -11.02 | -27.42 | |||||
Capital Expenditures, 5 Yr. CAGR % | -28.65 | -36.66 | -32.08 | 1.54 | - | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -0.48 | -3.91 | -8.52 | -1.04 | -36.31 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -0.7 | -4.06 | -8.63 | -1.06 | -36.75 |
- Stock Market
- Equities
- CYAD Stock
- Financials Celyad Oncology SA
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















